Tech Transfer Central
University-Industry Engagement Week

University-Industry Engagement Week provides a weekly round-up of current news and information in the world of industry engagement, delivered to your inbox every week (sign up here). It is published by University-Industry Engagement Advisor newsletter, which is available as a monthly subscription. For more information or to subscribe click here.

Sloan Kettering partners with Biodesix to develop new cancer diagnostics

Memorial Sloan Kettering Cancer Center (MSK) and diagnostics company Biodesix have entered into a new master collaborative research agreement (MCRA) to develop diagnostic tests aimed at improving cancer treatment.

Through the agreement, Biodesix will utilize its range of genomics, proteomics and data mining technologies to develop and commercialize oncology biomarker assays in collaboration with MSK. Bio-Rad, a leading developer of life science technologies and a partner of Biodesix, will provide its PCR assay technology in support of the collaboration.

The partnership aims to develop highly multiplexed digital PCR assays to enhance oncology offerings and support treatment decisions for lung cancer patients. Biodesix is known for its diagnostic tests for lung diseases, including the Nodify Lung Nodule Risk Assessment and the IQLung strategy for lung cancer patients.

“The expansion of our previous master sponsored research agreement into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics,” says Biodesix CEO Scott Hutton. “Biodesix looks forward to co-developing and validating new test concepts under these agreements.”

Simon May, president of life sciences at Bio-Rad Laboratories, comments, “We look forward to working with Biodesix to develop the next generation of highly multiplexed digital PCR assays as part of our expanding oncology offering. Bio-Rad provides the leading solution for digital PCR, and we are committed to providing oncology researchers and commercial partners with technologies that enable everything from biomarker discovery to clinical trials and patient monitoring of minimal residual disease.”

Source: BioSpace

Posted under: University-Industry Engagement Week